CN Patent

CN114828856B — 以稠合嘧啶化合物为有效成分的治疗剂

Assigned to Taiho Pharmaceutical Co Ltd · Expires 2024-11-05 · 2y expired

What this patent protects

本发明提供对慢性肾小球肾炎的新型治疗剂。其解决手段为一种慢性肾小球肾炎的治疗剂，其含有下述通式(I)所示的化合物或其盐作为有效成分。

USPTO Abstract

本发明提供对慢性肾小球肾炎的新型治疗剂。其解决手段为一种慢性肾小球肾炎的治疗剂，其含有下述通式(I)所示的化合物或其盐作为有效成分。

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: CN114828856B
Jurisdiction: CN
Classification: —
Expires: 2024-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Taiho Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.